The Library

Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans

Tools

Loeffelholz, Christian von, Möhlig, Matthias, Arafat, Ayman, M., Isken, Frank, Spranger, Joachim, Mai, Knut, Randeva, Harpal S., Pfeiffer, Andreas F. H. and Weickert, Martin O.. (2010) Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. European Journal of Endocrinology, Vol.162 (No.3). pp. 507-513. ISSN 0804-4643

PDF
WRAP_Weickert_-j-endocrinol_2010.pdf - Draft Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (382Kb)

Official URL: http://dx.doi.org/10.1530/EJE-09-0737

Abstract

Objective: To study the association of vaspin with glucose metabolism. Design: Cross-sectional and intervention study. Subjects and methods: The association of serum vaspin with metabolic and anthropometric characteristics was investigated in 108 volunteers. Euglycemic–hyperinsulinemic clamps (EHC) were performed in 83 of the participants. Changes of circulating vaspin levels were additionally studied in a crossover study using 300 min EHC with lipid versus saline infusion (n=10). Results: Neither glucose tolerance status nor insulin sensitivity, both as measured using EHCs and using homeostasis model assessment for insulin resistance (HOMA-IR), was significantly associated with serum vaspin in the cross-sectional study. Furthermore, there was no effect of short-term lipid-induced insulin resistance due to a 300 min intravenous lipid challenge on circulating vaspin. However, circulating vaspin levels were significantly elevated in women using oral contraceptives (OC), both compared to women without OC intake (1.17±0.26 vs 0.52±0.09 ng/ml, P=0.02) and males (1.17±0.26 vs 0.29±0.04 ng/ml, P=0.01). After exclusion of OC using females and stratification according to body mass index (BMI), a significant sexual dimorphism in subjects with a BMI <25 kg/m2 was observed (males 0.21±0.04 ng/ml versus females 0.70±0.16 ng/ml, P=0.009). Conclusion: Our results support the existence of a sexual dimorphism regarding circulating vaspin. The lack of an association of serum vaspin with HOMA-IR and M value indicates, however, no major role for vaspin concerning insulin sensitivity in nondiabetic humans.

Item Type:	Journal Article
Alternative Title:	Serum vaspin and insulin sensitivity
Subjects:	Q Science > QP Physiology
Divisions:	Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Blood sugar, Insulin, Serine proteinases -- Inhibitors, Adipose tissues
Journal or Publication Title:	European Journal of Endocrinology
Publisher:	BioScientifica Ltd.
ISSN:	0804-4643
Date:	1 March 2010
Volume:	Vol.162
Number:	No.3
Page Range:	pp. 507-513
Identification Number:	10.1530/EJE-09-0737
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke [German Institute of Human Nutrition Potsdam-Rehbrücke]
References:	1. Rabe K, Lehrke M, Parhofer KG & Broedl UC: Adipokines and insulin resistance. Molecular Medicine 2008 14 741-751. 2. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H & Kanwar YS: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Science U S A 2005 102 10610-10615. 3. Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M & Blüher M: Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochemical and Biophysical Research Communications 2006 339 430-436. 4. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T & Takahashi T: A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. Journal of International Medical Research 2008 36 625-629. 5. Wada J: Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opinion on Investigational Drugs 2008 17 327-333. 6. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M & Blüher M: Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008 57 372-377. 7. Gulcelik NE, Karakaya J, Gedik A, Usman A & Gurlek A: Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. European Journal of Endocrinology 2009 160 65-70. 8. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H & Randeva HS: Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008 57 1501-1507. 9. Handisurya A, Riedl M, Vila G, Maier C, Clodi M, Prikoszovich T, Ludvik B, Prager G, Luger A & Kautzky-Willer A: Serum Vaspin Concentrations in Relation to Insulin Sensitivity Following RYGB-Induced Weight Loss. Obesity Surgery 2009. 10. Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Blüher M, Stumvoll M & Fasshauer M: Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. Journal of Clinical Endocrinology and Metabolism 2008 93 247-251. 11. Aust G, Richter O, Rohm S, Kerner C, Hauss J, Kloting N, Ruschke K, Kovacs P, Youn BS & Blüher M: Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009 204 262-266. 12. Boden G, Chen X, Ruiz J, White JV & Rossetti L: Mechanisms of fatty acid-induced inhibition of glucose uptake. Journal of Clinical Investigation 1994 93 2438-2446. 13. Weickert MO, Loeffelholz CV, Roden M, Chandramouli V, Brehm A, Nowotny P, Osterhoff MA, Isken F, Spranger J, Landau BR, Pfeiffer AF & Möhlig M: A Thr94Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects. American Journal of Physiology Endocrinology and Metabolism 2007 293 E1078-1084. 14. Fischer A, Fisher E, Möhlig M, Schulze M, Hoffmann K, Weickert MO, Schueler R, Osterhoff M, Pfeiffer AF, Boeing H, et al.: KCNJ11 E23K affects diabetes risk and is associated with the disposition index: results of two independent German cohorts. Diabetes Care 2008, 31:87-89. 15. DeFronzo RA, Tobin JD & Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979 237 E214-223. 16. Weickert MO, Möhlig M, Spranger J, Schofl C, Loeffelholz CV, Riepl RL, Otto B & Pfeiffer AF: Effects of euglycemic hyperinsulinemia and lipid infusion on circulating cholecystokinin. Journal of Clinical Endocrinology and Metabolism 2008 93 2328-2333.
URI:	http://wrap.warwick.ac.uk/id/eprint/3400